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A B S T R A C T
Purpose: Our previous study using proteomic analysis showed that superoxide dismutase 1 (SOD1) was
signiﬁcantly decreased in cerebrospinal ﬂuid (CSF) of patients with epilepsy. However, the relevance of
CSF-SOD1 alterations for the pathophysiology of epilepsy is currently unknown. The present study was
intended to add to our understanding of this issue by measuring SOD1 levels in the CSF of patients with
resistant epilepsy and non-resistant epilepsy.
Methods: A total of 52 patients with epilepsy were recruited. 29 were non-resistant, 23 drug-resistant.
20 individuals with no evidence of any neurological diseases were used as control. The concentration of
CSF and serum SOD1 was measured by enzyme-linked immunosorbent assay.
Results: The concentration of CSF-SOD1 was decreased in both the drug-resistant (0.13  0.12 ng/ml) and
the non-resistant epilepsy subgroups (0.29  0.23 ng/ml) compared to the control group (0.40  0.35 ng/ml).
SOD1 was signiﬁcantly lower in the drug-resistant than the non-resistant epilepsy subgroup (P < 0.05).
Conclusion: SOD1 levels are decreased in the CSF of patients with epilepsy, especially of patients with
intractable epilepsy. Low CSF-SOD1 levels may be a predictor of antiepileptic drug resistance in patients
with epilepsy.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Superoxide dismutase (SOD) is a key antioxidant enzyme,
which cleans the superoxide radical and forms the ﬁrst line of
defense against oxidative stress and its subsequent effects. Three
isoforms of SOD exist in human cells, including cytosolic (Cu, Zn-
SOD; SOD1), mitochondrial (Mn-SOD; SOD2) and extracellular (EC-
SOD, SOD3).1 SOD1 isoenzyme has been proved to be associated
with neurodegenerative diseases, such as amyotrophic lateral
sclerosis.2 Prolonged seizures may result in mitochondrial
dysfunction, increased production of reactive oxygen species
and nitric oxide, accelerating neuronal cell death, and ﬁnally
causing epileptogenesis via mitochondrial apoptosis.3 Thus,
mitochondrial oxidative stress and dysfunction are considered
key factors to epileptogenesis.4 Therefore, SOD1 has a strong link to
epilepsy-related oxidative stress and apoptosis.
A recent study has indicated that SOD1 can be secreted into and
tested in cerebrospinal ﬂuid (CSF).5 Therefore, CSF-SOD1 changes
can represent alteration of the brain. A previous study from our
laboratory showed that the SOD1 level had signiﬁcantly decreased* Corresponding author. Tel.: +86 23 89012878; fax: +86 23 68708697.
E-mail address: xfyp2008@gmail.com (X. Wang).
1 These authors contributed equally to this study.
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http://dx.doi.org/10.1016/j.seizure.2012.05.003in the CSF of patients with epilepsy by proteomic analysis.6 We
hypothesize that decreased SOD1 may attenuate anti-apoptosis
activity, thus leading to seizure-induced neuronal death in the
brain; seizures eventually become intractable.
Intractable epilepsy is a complicated condition in clinical
practice, and remains a diagnostic and therapeutic challenge to
date. Physicians are still seeking useful factors to assist with
diagnosing intractable epilepsy and predicting the prognosis.
Hence, we designed this study to detect whether SOD1 can be used
as a predicting factor for intractable epilepsy.
2. Methods
2.1. Patients and samples
A total of 52 patients (28 males, 24 females) were randomly
recruited from the epilepsy center of The First Afﬁliated Hospital of
Chongqing Medical University, Chongqing, Southwest China. The
mean age of patients was 29.73  12.87 years; ages ranged from 11
years to 60 years. All patients had a comprehensive clinical
examination (including a medical history, neurological and psychiat-
ric examination and electroencephalogram). Cranial magnetic reso-
nance imaging and computed tomography scans found no
progressive lesions in the central nervous system. Patients were
diagnosed as idiopathic epilepsy according to the criteria proposed byvier Ltd. All rights reserved.
Table 1
Clinical material of the patients in the study.
Number Age (years) Gender Age of onset (years) Duration of seizures (years) AEDs prescribed AEDs response Clinical phenotype
1 13 M 10 3 VPA Effective GTCS
2 13 F 12 1 PB Effective GTCS
3 56 M 55 1.5 CBZ Effective CPS
4 54 M 53 1.25 CBZ Effective SPS
5 33 M 29 4 VPA Effective SPS
6 43 M 42 1 TPM Effective CPS
7 17 M 16 1.33 LEV Effective CPS-GTCS
8 60 M 58 2 VPA Effective CPS
9 48 F 45 2.83 TPM Effective SPS
10 24 F 23 1.25 VPA Effective GTCS
11 23 F 19 4.17 VPA, CBZ Effective CPS
12 30 F 29 1 LTG Effective GTCS
13 45 M 43 1.67 VPA Effective CPS
14 17 M 15 2.08 VPA Effective CPS
15 24 F 21 3 TPM Effective GTCS
16 23 F 21 1.83 TPM Effective CPS
17 31 F 28 3 VPA Effective CPS-GTCS
18 42 M 40 2 LEV Effective SPS
19 18 F 16 2 VPA Effective CPS
20 23 F 20 2.67 VPA Effective SPS
21 23 F 20 3 TPM Effective SPS
22 28 F 26 2.25 VPA Effective CPS
23 42 M 40 2 CBZ Effective CPS
24 22 F 20 1.75 TPM Effective GTCS
25 46 M 45 1 CBZ Effective SPS
26 20 M 18 2 VPA Effective CPS
27 35 M 32 2.58 VPA Effective CPS
28 37 F 35 1.92 CBZ Effective SPS
29 16 M 14 2 VPA Effective SPS
30 41 M 1 40 CBZ, PB, VPA, TPM Resistant CPS-GTCS
31 11 M 2 9 VPA, TPM, LTG Resistant CPS-GTCS
32 38 M 30 8 CBZ, VPA, TPM Resistant GTCS
33 39 M 9 30 CBZ, VPA, TPM Resistant CPS
34 24 F 14 10 CBZ, VPA, TPM, LTG Resistant GTCS
35 22 F 8 14 CBZ, VPA, TPM, LEV Resistant CPS-GTCS
36 28 M 8 20 VPA, TPM, LEV Resistant CPS
37 13 F 9 4.25 CBZ, VPA, TPM Resistant CPS
38 41 M 17 24 VPA, TPM, LEV Resistant GTCS
39 13 F 4 9 VPA, TPM, LTG Resistant GTCS
40 33 M 25 8 CBZ, PB, VPA, TPM Resistant CPS-GTCS
41 51 F 30 21 CBZ, VPA, TPM Resistant CPS
42 11 M 2 9 CBZ, VPA, TPM, LEV Resistant GTCS
43 38 M 20 18 CBZ, VPA, TPM Resistant GTCS
44 26 F 1 25 CBZ, VPA, TPM, PB Resistant CPS
45 37 F 7 30 VPA, TPM, PB, LEV Resistant GTCS
46 17 M 9 8 CBZ, VPA, TPM, PB Resistant GTCS
47 20 M 2 18 VPA, TPM, PB, LEV Resistant CPS-GTCS
48 32 F 28 4 CBZ, VPA, TPM, PB Resistant CPS
49 45 M 39 5.5 CBZ, VPA, TPM, PB Resistant GTCS
50 28 M 12 16 VPA, LTG, TPM, LEV Resistant GTCS
51 15 F 0 15 CBZ, VPA, TPM, LEV Resistant CPS-GTCS
52 17 F 2 15 CBZ, VPA, TPM, PB Resistant GTCS
F, female; M, male; VPA, valproate acid; PB, phenobarbital; CBZ, carbamazepine; TPM, topiramate; LTG, lamotrigine; GTCS, generalized seizure; CPS, complex partial seizure;
SPS, simple partial seizure.
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etiology. According to therapeutic efﬁcacy, these patients were
divided into two groups, which were non-resistant epilepsy subgroup
(n = 29) and drug-resistant subgroup (n = 23). Patients in the drug-
resistant subgroup have taken a variety of anti-epilepsy drugs with
the outcome of having no response to them. Patients in the non-
resistant epilepsy subgroup responded to at least one AED. The age,Table 2
Clinical characteristics of the subjects.
Non-resistant epilepsy subgroup (n = 29) Dru
Age (years) 31.24  13.56 27.8
Gender
Female 14 10 
Male 15 13 
Duration of seizures 2.11  0.84 (years) 15.6gender, clinical phenotype, duration of the illness and AEDs
prescribed to the patients are presented in Table 1. We studied only
patients whose last presenting seizure was within 1 week before the
CSF was taken, to avoid interference from recent seizure outbreaks. In
addition, 20 age- and gender-matched individuals (11 males, 9
females) with a mean age of 36.15  15.82 years were used as
controls. All controls had no history of neuropsychological diseasesg-resistant epilepsy subgroup (n = 23) Control (n = 20) P value
3  11.98 36.15  15.82 >0.05
9 >0.05
11
8  9.37 (years) Not applicable <0.05
Table 3
Individual data of SOD1 concentration.
Number AEDs response CSF-SOD1 (ng/ml) Serum-SOD1 (ng/ml)
1 Effective 0.053558 27.479
2 Effective 0.691305 56.73357
3 Effective 0.069179 66.98752
4 Effective 0.569162 59.86435
5 Effective 0.020217 17.71542
6 Effective 0.527824 65.58668
7 Effective 0.540213 56.53018
8 Effective 0.163293 46.4837
9 Effective 0.113965 34.1654
10 Effective 0.497179 53.69532
11 Effective 0.021294 19.3781
12 Effective 0.542607 57.28215
13 Effective 0.3996 44.34351
14 Effective 0.104271 27.02426
15 Effective 0.072028 26.32222
16 Effective 0.47948 47.61037
17 Effective 0.052025 18.30925
18 Effective 0.399718 27.57958
19 Effective 0.150966 43.84992
20 Effective 0.071367 41.1741
21 Effective 0.073285 42.06813
22 Effective 0.146085 44.04236
23 Effective 0.210836 46.58687
24 Effective 0.386092 49.3081
25 Effective 0.790457 49.36262
26 Effective 0.221091 46.93876
27 Effective 0.158554 48.95918
28 Effective 0.486995 46.48568
29 Effective 0.499822 27.56771
30 Resistant 0.01349 15.93726
31 Resistant 0.11316 36.86772
32 Resistant 0.112469 34.96025
33 Resistant 0.04319 14.53462
34 Resistant 0.093169 25.12339
35 Resistant 0.090218 26.20654
36 Resistant 0.052184 23.37034
37 Resistant 0.363031 38.8674
38 Resistant 0.051718 21.30456
39 Resistant 0.110146 37.51832
40 Resistant 0.334948 38.57528
41 Resistant 0.031758 19.16817
42 Resistant 0.236085 36.84209
43 Resistant 0.045703 23.10859
44 Resistant 0.030701 24.32866
45 Resistant 0.031327 17.03814
46 Resistant 0.294067 38.5507
47 Resistant 0.081935 25.3268
48 Resistant 0.361017 38.88487
49 Resistant 0.339004 42.41377
50 Resistant 0.076967 24.72433
51 Resistant 0.060952 37.68281
52 Resistant 0.062309 40.89081
53 Control 0.240346 29.04783
54 Control 0.044644 43.82076
55 Control 0.052442 35.84117
56 Control 0.124817 36.27898
57 Control 0.233187 47.41592
58 Control 1.03425 59.10847
59 Control 0.837185 68.33119
60 Control 0.54966 39.85017
61 Control 0.052168 24.63059
62 Control 0.803762 38.75797
63 Control 0.058312 21.17647
64 Control 0.594926 12.14929
65 Control 0.192258 23.7502
66 Control 0.358117 10.436516
67 Control 0.639547 20.20148
68 Control 0.373757 24.05624
69 Control 1.192635 46.27052
70 Control 0.321349 37.82785
71 Control 0.204971 29.6402
72 Control 0.131226 21.06782
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clinical data of all participants. Informed consent was obtained from
all participants.
4 ml CSF and 5 ml venous blood were collected from patients
and controls. The total protein and biochemistry of CSF and blood
were analyzed, and remaining CSF was centrifuged at 2000 rpm for
10 min at 4 8C to separate cell components, the remaining blood
was centrifuged at 3000 rpm for 15 min to collect the serum. All
samples were stored at 80 8C for later analysis.
2.2. Ethics
This trial was approved by the ethics committee on human
research at Chongqing Medical University.
2.3. Enzyme-linked immunosorbant assays (ELISA)
CSF SOD1 was determined using ELISA, with the Human SOD1
Elisa Kit (Uscn Life Science & Technology Company, Wuhan, China),
following the manufacturer’s instructions. Dilution of the serum
and CSF were 1:10 and 1:5, respectively. The assay procedure was
as follows: add 100 ml of standard, blank, and samples per well and
incubate for 2 h at 37 8C covering with plate sealer. Then remove
the liquid from each well and add 100 ml detection reagent A
working solution to each well and incubate for 1 h at 37 8C. Then
aspirate each well and wash by ﬁlling each well with wash buffer
using multichannel pipettor, repeating the process three times.
After that, add 100 ml detection reagent B working solution to each
well and incubate for 1 h at 37 8C and repeat the aspirate and wash
steps. Then add 90 ml substrate solution to each well and incubate
for 30 min at 37 8C, protecting from light. Add 50 ml stop solution
to each well, if color change does not appear uniform. Finally,
determine the optical density of each well at once, using a
microplate reader set to 450 nm on Multiscan Spectrum Micro-
plate Spectrophotometer (Thermo Fisher Scientiﬁc, USA).
2.4. Statistical analysis
Descriptive data were expressed as means  standard deviation
(S.D.). Independent sample t-test and one-way analysis of variance
(ANOVA) were used. A P-value less than 5% was considered as
signiﬁcant. Statistical analysis was performed using SPSS statistics
software, version 11.5.
3. Results
CSF-total protein was 0.41  0.15 g/l in the non-resistant
epilepsy subgroup, 0.45  0.23 g/l in the drug-resistant epilepsy
subgroup, and 0.47  0.09 g/l in the controls. Serum-total protein was
61.66  4.22 g/l in the non-resistant epilepsy subgroup,
62.35  3.46 g/l in the drug-resistant epilepsy subgroup, and
61.30  3.80 g/l in the controls. The total protein of CSF and serum
had no signiﬁcant difference in the non-resistant, drug-resistant
patients subgroup and control group (P > 0.05).
The concentration of CSF-SOD1 was 0.13  0.12 ng/ml in the
drug-resistant subgroup, 0.29  0.23 ng/ml in the non-resistant
epilepsy subgroup, and 0.40  0.35 ng/ml in the controls. One-way
ANOVA analysis showed that the difference between the three groups
was signiﬁcant (P < 0.05). Dunnett-t test showed that the concentra-
tion of CSF-SOD1 in the drug-resistant epilepsy subgroup was lower
than that in the controls (P < 0.05), and there was no signiﬁcant
difference of concentration of CSF-SOD1 between the non-resistant
epilepsy subgroup and the controls (P > 0.05). There was a signiﬁcant
difference of CSF-SOD1 between the drug-resistant epilepsy subgroup
and the controls.
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group, 42.74  13.88 ng/ml in the non-resistant epilepsy subgroup,
and 33.48  14.87 ng/ml in the controls. One-way ANOVA analysis
showed that there were signiﬁcantly differences between the three
groups (P < 0.05). Dunnett-t test showed serum-SOD1 level in the
drug-resistant subgroup was not signiﬁcantly lower than that in the
controls (P > 0.05). No statistically signiﬁcant difference was found
between the non-resistant epilepsy subgroup and the controls
(P > 0.05). The signiﬁcant difference of serum-SOD1 existed between
the drug-resistant epilepsy subgroup and the drug-effective epilepsy
subgroup.
4. Discussion
The present study indicates that the SOD1 concentration is
decreased in the CSF of patients with epilepsy, and decreased CSF-
SOD1 is more obvious in the subgroup of drug-resistant epilepsy
than that in the non-resistant epilepsy subgroup and the controls.
To our knowledge, our group ﬁrstly reported the alterations of CSF-
SOD1 in patients with epilepsy.
The human SOD1 gene is located on chromosome 21q22.11. The
protein encoded by this gene binds copper and zinc ions and
responds to destroy free superoxide radicals in the body. The
encoded soluble cytoplasmic protein acts as a homodimer to
convert naturally occurring but harmful superoxide radicals to
molecular oxygen and hydrogen peroxide. Mutations in this gene
have been implicated as causes of familial amyotrophic lateral
sclerosis.2 SOD1 works as a multifunctional protein, associated
with oxidative stress, excitotoxicity, mitochondria dysfunction.7 In
the present study, decreased CSF-SOD1 level shows that the SOD1
protective function is attenuated in response to epilepsy.
Mutations of the SOD1 gene contribute to neuronal injuries in
the cerebrum, brain stem and spinal cord, and to enhancement of
oxidizing reaction, and thus misfolded proteins, triggering familial
amyotrophic lateral sclerosis.8 In addition, SOD1 also participates
in apoptosis, including nitric oxide-dependent and mitochondria-
dependent.9,10 Therefore, SOD1 is an important factor in neuronal
apoptosis. It is well established that apoptosis and oxidative stress
are important pathophysiological processes in the development of
epilepsy,11,12 and decreased SOD1 means attenuation of anti-
oxidative and anti-apoptotic activities via various transcriptional
pathways,13 contributing to development of epilepsy.
Although this study has found that SOD1 is decreased in the CSF
of patients with epilepsy, it is impossible to use human samples for
studying the role of SOD1 in the genesis and development of
human epilepsy due to ethic limitation. Therefore, animal models
with epilepsy will be further tested for the mechanisms of
epileptogenesis based on SOD1 alterations.
The present study indicates that SOD1 has been markedly
decreased in the CSF of patients with intractable epilepsy
compared to the CSF of patients with epilepsy. Therefore, CSF-
SOD1 alterations can probably be used as a predicting factor forintractable epilepsy; epileptic patients with decreased CSF-SOD1
are apt to be drug-resistant. However, no reference value is
concluded to distinguish intractable epilepsy and drug-effective
epilepsy due to the limited sample size. In addition, the role of
serum-SOD1 change is different compared to CSF-SOD1 change,
we thus think that peripheral SOD1 does not reﬂect the change in
the central environment. Further study will be performed to
expand the samples to conﬁrm the reference value for the
diagnosis of intractable epilepsy.
In conclusion, SOD1 levels are decreased in the CSF of human
epilepsy. Decreased levels of SOD1 are associated with repeated
seizures. Therefore, decreased CSF-SOD1 might be a potential
factor for predicting intractable epilepsy.
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